CRVS
Price
$7.20
Change
-$0.27 (-3.61%)
Updated
Oct 21 closing price
Capitalization
536.5M
8 days until earnings call
Intraday Buy/Sell Signals
RZLT
Price
$8.86
Change
-$0.15 (-1.66%)
Updated
Oct 21 closing price
Capitalization
804.74M
15 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CRVS vs RZLT

Header iconCRVS vs RZLT Comparison
Open Charts CRVS vs RZLTBanner chart's image
Corvus Pharmaceuticals
Price$7.20
Change-$0.27 (-3.61%)
Volume$528.16K
Capitalization536.5M
Rezolute
Price$8.86
Change-$0.15 (-1.66%)
Volume$2.14M
Capitalization804.74M
CRVS vs RZLT Comparison Chart in %
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. RZLT commentary
Oct 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and RZLT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 22, 2025
Stock price -- (CRVS: $7.20 vs. RZLT: $8.86)
Brand notoriety: CRVS and RZLT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 66% vs. RZLT: 164%
Market capitalization -- CRVS: $536.5M vs. RZLT: $804.74M
CRVS [@Biotechnology] is valued at $536.5M. RZLT’s [@Biotechnology] market capitalization is $804.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $109.29B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileRZLT’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • RZLT’s FA Score: 0 green, 5 red.
According to our system of comparison, RZLT is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 3 TA indicator(s) are bullish while RZLT’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 3 bullish, 5 bearish.
  • RZLT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RZLT is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а +2.27% price change this week, while RZLT (@Biotechnology) price change was +5.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.78%. For the same industry, the average monthly price growth was +16.12%, and the average quarterly price growth was +65.35%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 30, 2025.

RZLT is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RZLT($805M) has a higher market cap than CRVS($537M). RZLT YTD gains are higher at: 80.816 vs. CRVS (34.579). CRVS has higher annual earnings (EBITDA): -35.45M vs. RZLT (-77.12M). RZLT has more cash in the bank: 86.9M vs. CRVS (74.4M). CRVS has less debt than RZLT: CRVS (1.08M) vs RZLT (1.78M). CRVS (0) and RZLT (0) have equivalent revenues.
CRVSRZLTCRVS / RZLT
Capitalization537M805M67%
EBITDA-35.45M-77.12M46%
Gain YTD34.57980.81643%
P/E RatioN/AN/A-
Revenue00-
Total Cash74.4M86.9M86%
Total Debt1.08M1.78M61%
FUNDAMENTALS RATINGS
CRVS vs RZLT: Fundamental Ratings
CRVS
RZLT
OUTLOOK RATING
1..100
7464
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3737
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RZLT's Valuation (35) in the null industry is somewhat better than the same rating for CRVS (68) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

CRVS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as RZLT (99) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

CRVS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as RZLT (37) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

CRVS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSRZLT
RSI
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 7 days ago
89%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIDAX33.25N/A
N/A
MFS International New Discovery A
BEQAX38.06N/A
N/A
American Century Equity Growth A
MVEIX11.83N/A
N/A
Monteagle Select Value I
JRSDX12.82-0.02
-0.16%
JH Adaptive Risk Mgd U.S. Eq D
IGNCX14.95-0.42
-2.73%
Macquarie Natural Resources C

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-3.61%
SYRE - CRVS
43%
Loosely correlated
-1.02%
IPSC - CRVS
42%
Loosely correlated
-0.96%
TERN - CRVS
41%
Loosely correlated
-5.80%
RZLT - CRVS
41%
Loosely correlated
-1.66%
UPB - CRVS
39%
Loosely correlated
-3.12%
More

RZLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RZLT has been loosely correlated with DYN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RZLT jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RZLT
1D Price
Change %
RZLT100%
-1.66%
DYN - RZLT
45%
Loosely correlated
-1.93%
SYRE - RZLT
44%
Loosely correlated
-1.02%
AVBP - RZLT
44%
Loosely correlated
-2.00%
TERN - RZLT
43%
Loosely correlated
-5.80%
CRNX - RZLT
43%
Loosely correlated
+0.94%
More